ForsLean (Coleus forskohlii extract)

ForsLean is a patented Coleus forskohlii root extract standardized to 10% forskolin, a labdane diterpene that directly activates adenylyl cyclase to raise intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A, accelerating lipolysis and supporting favorable changes in body composition.

Origin & History

ForsLean is a patented extract from the roots of Coleus forskohlii, a plant native to India in the mint family. The extract is produced by Sabinsa through standardized extraction methods, yielding forskolin concentrations ranging from 10% to 98%, with forskolin being a labdane diterpenoid compound.

Historical & Cultural Context

Coleus forskohlii roots have been used in Indian traditional medicine (Ayurveda) as part of vegetarian meals and for various pharmacological properties. Modern scientific interest arose from its identification as a source of the diterpene compound forskolin, though specific traditional applications and duration of use are not well documented.

Health Benefits

• Reduces body fat percentage: Clinical trial showed reduction from 28.3% to 26.5% over 12 weeks (moderate evidence)
• Increases lean body mass: Significant improvements observed in the same 12-week study (moderate evidence)
• Decreases hip circumference: Statistically significant reduction demonstrated in overweight/obese adults (moderate evidence)
• Supports cardiovascular function: Acts as a vasodilator and positive inotropic agent (preliminary evidence)
• Promotes fat metabolism: Activates hormone-sensitive lipase for enhanced lipolysis (mechanistic evidence)

How It Works

Forskolin, the primary bioactive in ForsLean, directly activates the enzyme adenylyl cyclase independent of G-protein receptor stimulation, converting ATP to cyclic AMP (cAMP). Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL), triggering the breakdown of stored triglycerides into free fatty acids via lipolysis. Simultaneously, PKA activation may stimulate thyroid hormone secretion and increase expression of androgen receptors in skeletal muscle, contributing to lean mass preservation and gains.

Scientific Research

A randomized, double-blind, placebo-controlled trial tested ForsLean (10% forskolin) at 500mg daily for 12 weeks in 36 overweight/obese adults (30 completed), demonstrating significant reductions in body fat percentage and hip circumference with increases in lean body mass. No meta-analyses or additional RCTs were identified in the available research, though the primary study reported no adverse events or changes in vital signs.

Clinical Summary

The most cited human trial is a randomized, double-blind, placebo-controlled study by Godard et al. (2005) involving 30 overweight men over 12 weeks using 250 mg of ForsLean (10% forskolin) twice daily. Subjects in the ForsLean group demonstrated a statistically significant reduction in body fat percentage from approximately 28.3% to 26.5% and significant increases in lean body mass compared to placebo. A parallel study in overweight women showed attenuation of weight gain rather than active fat loss, suggesting sex-dependent responses. Overall evidence is rated moderate, as most trials use small sample sizes and short durations, and independent replication remains limited.

Nutritional Profile

ForsLean is a standardized extract of Coleus forskohlii root, standardized to 10% forskolin (the primary bioactive diterpene compound). At a typical 250mg serving dose, this provides approximately 25mg of active forskolin. Forskolin (7beta-acetoxy-8,13-epoxy-1alpha,6beta,9alpha-trihydroxy-labd-14-ene-11-one) is a labdane-type diterpene that functions as the principal bioactive constituent. The extract contains negligible macronutrients — essentially zero protein, fat, and carbohydrates at typical supplemental doses. No meaningful vitamins or dietary minerals are present in pharmacologically relevant quantities. Additional minor diterpene compounds present in the root extract include 1,9-dideoxyforskolin, deacetylforskolin, and 9-deoxyforskolin, though these are present in smaller concentrations and have lower biological activity than forskolin itself. Forskolin bioavailability is moderate; it is lipophilic and absorbs reasonably well through the gastrointestinal tract, with peak plasma concentrations typically reached within 1–2 hours post-ingestion. Absorption may be enhanced when taken with a small amount of dietary fat due to its lipophilic nature. The mechanism of action is well-characterized: forskolin directly activates adenylyl cyclase, raising intracellular cyclic AMP (cAMP) levels, which in turn activates protein kinase A (PKA), stimulating hormone-sensitive lipase and promoting lipolysis. No fiber, amino acids, or essential fatty acids are present at meaningful levels in this extract.

Preparation & Dosage

Clinically studied dosage: 250mg twice daily (500mg total) of ForsLean standardized to 10% forskolin, providing 25mg active forskolin daily, taken for 12 weeks. Available in standardized forms containing 10-98% forskolin, typically in capsule form. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, CLA (conjugated linoleic acid), chromium picolinate, L-carnitine, cayenne pepper extract

Safety & Interactions

ForsLean is generally well tolerated at the clinically studied dose of 250 mg twice daily, with mild gastrointestinal discomfort and transient hypotension reported in some users due to forskolin's vasodilatory cAMP-mediated effects. It carries a significant interaction risk with antihypertensive medications, anticoagulants such as warfarin, and antiplatelet drugs because forskolin can potentiate vasodilation and inhibit platelet aggregation. Individuals with bleeding disorders, hypotension, or those taking beta-blockers should avoid use without physician supervision, as cAMP elevation can increase heart rate and alter cardiac contractility. Safety data during pregnancy and lactation are insufficient, and use is not recommended in these populations.